The drugmaker said it has started a two-year program to prepare for the spinoff company to launch in 2022. The new company will focus on immune system drugs, genetics and new technologies and could become the largest seller of such drugstore basics as Advil and Tums.
The company plans to focus on research and development and new product launches this year and is considering divesting some non-core assets, such as its prescription dermatology business. It is trying to save $910 million by 2022.
GlaxoSmithKline also plans to cut as many as 720 jobs from its vaccine unit in Belgium, according to FirstWord Pharma.
Read the full article here.
More articles on pharmacy:
How 4 hospital pharmacies are improving operations
The 10 most-valued pharma brands in the world
Merck to create spinoff women’s health company, focus on Keytruda
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.